Specifically, PPARα/β promotes bone resorption,130 whereas PPARγ is known inhibitors of osteoclastogenesis.131 Roles of PPARγ in osteoblasts are still disputed; it has been shown that conditional deletion of PPARγ in osteoblasts enhances bone mass and increased bone formation by activating mTOR signalling,132 while studies from other groups reported conflicting results.133, 134, 135 Moreover, recent findings have indicated that treatment of multiple myeloma cells with PPARs resulted in apoptotic effects,136 suggesting PPARs might serve as promising therapeutic targets for bone diseases. This evidence concerns the gene PPARG and plasma cell myeloma.